Dr. Klaus Hollmig is originally from Germany and graduated from the Rheinische Friederich-Wilhelm University in Bonn, Germany, in 1994. He spent two years in translational research at the University of Duesseldorf and completed his clinical training at the University of Missouri-Columbia in internal medicine and the University of Alabama-Birmingham (UAB) in medical oncology.
From 2003 to 2011 he worked as a multiple myeloma disease specialist at the Myeloma Institute for Research and Therapy (MIRT) and as a general medical oncologist at the University Hospital and the Veteran’s Administration Hospital in Little Rock, AR.
Later on, Dr. Hollmig moved to the west coast as a general medical oncologist, treating all solid and hematologic malignancies and serving as a multiple myeloma specialist with referrals from Oregon, Idaho, and Washington State. As medical director, he provided leadership for the autologous transplant section of the Northwest Marrow Transplant Program in Portland, OR.
In 2013 Dr. Hollmig was recruited by UT Southwestern to develop the newly formed community medical oncology program with the first clinic location in Plano/Richardson.
Dr. Hollmig believes in treating aggressively for cure or to improve the quality of life of his patients. Every patient’s disease, wishes, and goals are different. It is the physician’s job to match these goals and find best suited treatment for each individual patient, while preserving as much quality of life during cancer therapy as possible. In his daily practice he encourages patient and family participation in all medical decision; while cancer care is highly based on evidence and guidelines, there are many ways to reconcile available options with patient’s and family’s wishes and preferences.
In his private time, Dr. Hollmig enjoys traveling, multihull sailing in the Caribbean, and trading the stock market. He is a big Harley-Davidson enthusiast and did actively ride for 20 years in Europe and the US.
- Medical School
- Rheinische Friedrich-Wilhelms (1994)
- University of Missouri School of Medicine, Columbia (1999), Internal Medicine
- University of Alabama Medical Center (2002), Hematology Oncology
- Ductal Carcinoma in SITU (DCIS)
- Inflammatory Breast Cancer
- Invasive Ductal Carcinoma
- Invasive Lobular Carcinoma
- Male Breast Cancer
- Medullary Breast Cancer
- Mucinous Breast Carcinoma
- Triple Negative Breast Cancer
- Tubular Breast Cancer
- Chronic Lymphocytic Leukemia (CLL)
- Hodgkin's Disease
- Multiple Myeloma
Medical Treatment of Blood Disorders (Hematology)
- Anemia in Chronic Kidney Disease
- Iron Deficiency Anemia
- Low & High Platelet Count
- Low or High White Blood Count (WBC)
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Multifactorial Deficiencies after Gastric Bypass
Medical Treatment of Cancer
- Adjuvant & Neoadjuvant Therapy
- Hormonal Therapy
- Management of Side Effects of Chemotherapy
- Targeted Therapy
- Breast Cancer Therapy & Treatment
- Hormonal Therapy for Breast Cancer
- Latest Chemotherapy Options for Breast Cancer
- Neoadjuvant Treatment for Breast Cancer
- Targeted Therapy for Breast Cancer
- Clinical trials for Multiple Myeloma
- Plasma cell disorders related to multiple myeloma
- Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
- Hoering A, Crowley J, Shaughnessy JD, Hollmig K, Alsayed Y, Szymonifka J, Waheed S, Nair B, van Rhee F, Anaissie E, Barlogie B Blood 2009 Aug 114 7 1299-305
- Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
- Nair B, Shaughnessy JD, Zhou Y, Astrid-Cartron M, Qu P, van Rhee F, Anaissie E, Alsayed Y, Waheed S, Hollmig K, Szymonifka J, Petty N, Hoering A, Barlogie B Blood 2009 Jun 113 26 6572-5
- Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
- Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD, Tricot G, Zangari M, Zeldis J, Barer S, Crowley J Blood 2008 Oct 112 8 3115-21
- Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
- Barlogie B, van Rhee F, Shaughnessy JD, Epstein J, Yaccoby S, Pineda-Roman M, Hollmig K, Alsayed Y, Hoering A, Szymonifka J, Anaissie E, Petty N, Kumar NS, Srivastava G, Jenkins B, Crowley J, Zeldis JB Blood 2008 Oct 112 8 3122-5
- Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
- Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E, Waldron J, Pineda-Roman M, Thertulien R, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Crowley J, Sawyer J Blood 2008 Jan 111 1 94-100
- High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
- van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B Blood 2007 Aug 110 3 827-32
- Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
- Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, Fassas A, Hollmig K, Pineda-Roman M, Shaughnessy J, Epstein J, Crowley J Blood 2006 Apr 107 7 2633-8
- Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
- Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J N. Engl. J. Med. 2006 Mar 354 10 1021-30
- Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant.
- Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R, Talamo G, Muwalla F, Anaissie E, Hollmig K, Tricot G Bone Marrow Transplant. 2004 Apr 33 8 823-8
- Down-regulation of IL-2 receptor alpha (CD25) characterizes human gammadelta-T cells rendered resistant to apoptosis after CD2 engagement in the presence of IL-12.
- Guo BL, Hollmig KA, Lopez RD Cancer Immunol. Immunother. 2002 Jan 50 11 625-37
- American Society for Blood and Bone Marrow Transplantation (2003)
- American Society of Clinical Oncology (1999)
- American Society of Hematology (1999)